Product Type: Inhibitor
CAS No.: 346688-38-8
MolecularFormula: C15H23NO2S
Molecular Weight: 281,4
Source: Synthetic
Purity: >98% (TLC); NMR (Conforms)
Solubility: May be dissolved in DMSO (10 mg/ml)
Appearance: White powder
PubChem CID: 9795739
Scientific Background: Potential treatment for Huntington’s disease, Parkinson’s disease, and schizophrenia (1,2). Able to reverse both hypo- and hyperdopaminergia depending on local dopamine concentrations without inducing catalepsy. This was originally attributed to functional dopamine D2 antagonism with fast on/off kinetics (“dopamine stabilizer”) (3). More recent studies have attributed pridopidine’s effects to its being a more potent sigma-1 ligand than a D2 ligand (4,5). Displays neuroprotective/restorative effects (6,7) and ameliorates central features of amyotrophic lateral sclerosis pathology (8) in a sigma-1-mediated manner.
References: 1. F Pettersson et al. 2010 J. Med. Chem. 53:2510.2. S Natesan et al. 2006 J. Pharmacol. Exp. Ther. 318:810.3. T Dyhring et al. 2010 Eur. J. Pharmacol. 628:19.4. K Sahlholm et al. 2015 Psychopharmacology (Berl) 232:3443.5. K Sahlholm et al. 2013 Mol. Psychiatry 18:12.6. V Francardo et al. 2019 Neurotherapeutics 16:465.7. D Ryskamp et al. 2017 Neurobiol. Dis. 7 97(Pt A):46.8. A Ionescu et al. 2019 Cell Death Dis. 10:210.
Field of Use: Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only.